Intravascular nano-bubbling oxygenator

Abstract

The present invention provides a intravascular nano-bubbling oxygenator comprises a catheter, capable of being inserted into a blood vessel to transport normal pressure to hyperbaric gas, comprising: a tube wall with one or two lumens, and an opening end, wherein the tube wall partially comprises a plurality of pores; a connector; a gas transporting apparatus, and a control panel with on-line data sensors connections.

Description

CROSS REFERENCE OF RELATED APPLICATION[0001]This is a Continuation application that claims priority to U.S. non-provisional application, application Ser. No. 11 / 868,528, filed Oct. 7, 2007, the entire contents of each of which are expressly incorporated herein by reference.NOTICE OF COPYRIGHT[0002]A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to any reproduction by anyone of the patent disclosure, as it appears in the United States Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.BACKGROUND OF THE PRESENT INVENTION[0003]The annual mortality rate for all lung diseases is estimated to be approximately 250,000 in the US in 2000. About 150,000 patients were related to acute, potentially reversible respiratory failure and 100,000 patients related to chronic respiratory failure due to chronic obstructive lung disease (COPD) or ch...

AI Technical Summary

Problems solved by technology

However, serious adverse effects may occur with prolonged duration of intensive respiratory support or high oxygen fraction.

These hazardous effects, including oxygen toxicity, barotraumas, altered hormone and enzyme systems, mechanical ventilation induced lung injury (VILI), disuse atrophy of skeleton muscles, and added to the morbidity and mortality rates for these patients.

Another approach to artificial lung function, extracorporeal membrane oxygenation (ECMO) constitutes a mechanism for prolonged pulmonary bypass, which has been developed and optimized over several decades but has limited clinical utility today as a state-of-the-art artificial lung.

Despite the numerous advances in the implementation of ECMO over the years, its core technology is unchanged and continues to face important limitations.

The limitations of ECMO include the requirement for a large and complex blood pump and oxygenator system, the necessity for a surgical procedure for cannulation, the need for systemic anticoagulation, the labor intensive implementation, the exceeding high cost, and a high rate of complications, including bleeding and infection, protein absorption, and platelet adhesion on the surface of the oxygenator membrane.

As a result of these limitations, the ECMO has become limited in its utility to select cases of neonatal respiratory failure, where reversibility is considered to be highly likely.

Previous efforts have achieved some success, and have taught much to pulmonary physiologists, but gas sparing or diffusion has not yet achieved the degree of gas exchanges optimally desired.

The insertion of the IVOX effectively introduced a large amount of gas transfer surface area (up to 600 cm2) without alternation of systemic hemodynamics; unfortunately, as with ECMO, the IVOX system has numerous limitations including a moderate rate of achievable gas exchange, difficulty in device implantation, a relatively high rate of adverse events, and a significant rate of device malfunctions, including blood-to-gas leaks due to broken hollow fibers.

Images